Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Canada / NCT02674100
Recruiting Observational

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

NCT02674100 · tracked via the Priya Life Science Canada tracker
Sponsor
University of Louisville
Phase
Observational
Started
2016-01
Last updated
2025-02-25

Condition(s) studied

Pancreatic Cancer

Investigational drug(s) / intervention(s)

Registry

Study summary

The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions.

The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician. Exclusion Criteria: * Have a cardiac pacemaker or ICD implant * Non-removable implants with metal parts near target lesion * Myocardial infarction within 3 months prior to enrollment * Not suitable for general endotracheal anesthesia

Primary outcome measure(s)

  • Adverse Events — Up to 5 years
    Prospective collection of All Adverse Events that will be categorized as either IRE related or Non-IRE related and will be graded per CTCAE v4.0

Trial sites (16)

FacilityCityRegionStatus
University of Alabama Birmingham Birmingham Alabama Recruiting
University of California San Diego San Diego California Recruiting
University of Colorado Denver Colorado Recruiting
University of South Florida Tampa Florida Recruiting
Augusta University Augusta Georgia Recruiting
University of Louisville Louisville Kentucky Recruiting
Johns Hopkins Hospital Baltimore Maryland Recruiting
Atlantic Health Millburn New Jersey Recruiting
Northwell Health Cancer Institute Lake Success New York Recruiting
Gibbs Cancer Research, Spartanburg Regional Healthcare System Spartanburg South Carolina Recruiting
Methodist Digestive Institute Dallas Texas Recruiting
McGill University Montreal Quebec Recruiting
Sanno Hospital Tokyo Japan Recruiting
Centro Medico Mexico City Mexico Recruiting
National Taiwan University Taipei Taiwan Recruiting
Freeman Hospital High Heaton United Kingdom Recruiting

Other trials for the same condition

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma Active, not recruiting
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer Recruiting
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis Recruiting
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer Recruiting
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02674100 on ClinicalTrials.gov ↗ ← All trials in Canada